Processa Pharmaceuticals, Inc. (PCSA)

2.1801 -0.0799 (-3.54%) As of 01:00PM EDT. Market open.

Processa Pharmaceuticals, Inc.

7380 Coca Cola Drive
Suite 106
Hanover, MD 21076
United States
443 776 3133
https://www.processapharmaceuticals.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sian E. Bigora Ph.D., Pharm.D.	Co-Founder and Chief Development & Regulatory Officer	184.87k	N/A	1960
Mr. James H. Stanker	Chief Financial Officer	160.2k	N/A	1958
Mr. Patrick Lin	Co-Founder, Chief Business & Strategy Officer	117.15k	N/A	1965
Ms. Wendy J. Guy	Co-Founder, Chief Administrative Officer & Corporate Secretary	94.19k	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Corporate governance

Processa Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.